Epitalon + Pinealon peptides

Estimated longevity benefit: +0.7 years. Evidence score: 64/100.

Overview

Epitalon and Pinealon are synthetic bioregulatory peptides that target telomere maintenance and pineal-brain function. By potentially reactivating telomerase and restoring circadian melatonin rhythms, they address central drivers of cellular and systemic aging.

Evidence assessment

Epitalon (Ala-Glu-Asp-Gly) and Pinealon (Glu-Asp-Arg, also called EDR peptide) are ultrashort synthetic peptides developed by Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology. They are combined because they are claimed to act synergistically — Epitalon stimulating melatonin synthesis and telomerase activation, Pinealon supporting sleep architecture and neuroprotection. The strongest human data comes from a 12-year randomized trial (Korkushko et al., 2006) in 70 elderly cardiovascular patients: those treated with epithalamin — the crude polypeptide precursor to synthetic Epitalon — had a 28% lower overall mortality rate, with roughly twice the cardiovascular mortality reduction of controls. A separate cohort study (Khavinson & Morozov, 2003) tracking 266 older adults over 6 years reported normalized immune, endocrine, and metabolic markers. On the molecular side, two studies show that Epitalon induces telomerase activity and elongates telomeres in human somatic cells: the original 2003 report by Khavinson et al. in human fibroblasts, and a 2025 independent study from Brunel University (Al-Dulaimi et al.) — the first external replication of this telomere mechanism across multiple human cell line types. Pinealon evidence comes from in vitro work showing the EDR tripeptide restores neuronal spine density in Alzheimer's disease models. The central limitation is that every significant clinical finding comes from a single research institution, with no independent replication of the human mortality data. A 2025 independent review by Polish researchers (Araj et al., Int J Mol Sci) concluded that critical safety data is missing and called for genotoxicity and drug interaction studies before any clinical approval. The original clinical trials used injectable Epithalamin — a crude bovine pineal extract — not oral synthetic Epitalon, which is the compound most people actually purchase and take. This intervention occupies a uniquely curious position: decades of consistent data from one prolific lab, a growing biohacker following, and almost no independent validation of the clinical claims. The biological mechanism is centered on the potential for these short peptides to cross the nuclear membrane and interact directly with DNA to influence gene expression related to telomerase activity and circadian regulation. Evidence is preliminary, with a strong focus on in vitro cell line studies and a small number of longitudinal trials from a single research group. A key nuance is that while the mechanistic data for telomere elongation is gaining independent support, the translation to human healthspan and the long-term safety of synthetic versions remains largely unproven.

Implementation protocol

Important disclaimers: The use of synthetic peptides like Epitalon and Pinealon is considered highly experimental, particularly when administered outside of a controlled research environment. Most available clinical data stems from a single research group using a crude extract, leaving significant gaps in our understanding of the safety and efficacy of modern synthetic versions. - The published clinical studies used intramuscular injections of Epithalamin (crude pineal extract), not oral synthetic Epitalon — the compound most people purchase - No human RCTs exist for oral synthetic Epitalon or Pinealon at any dose - No regulatory approval exists for longevity or anti-aging indications in any jurisdiction - Consult a physician before use — especially if taking any medications or with a history of cancer

Commonly reported oral protocol (biohacker consensus, not clinically validated): In the absence of established clinical guidelines for oral administration, many users follow protocols derived from community experience and preliminary biohacker consensus. These regimens typically emphasize the importance of timing and empty-stomach administration to maximize the potential bioavailability of the peptides. - Pinealon: 20 mg (typically 2 capsules) taken 30 min before bed on an empty stomach - Epitalon: 10 mg (typically 1 capsule) taken alongside Pinealon - Fasting window: No food for at least 2 hours before dosing - Cycle: 20–30 consecutive days, then 3 months off; repeat 2–3×/year - Some practitioners prefer the spring and autumn equinox windows, following traditional Russian clinical protocols

Injectable Epitalon (higher-risk, requires medical supervision): The injectable form of Epitalon is closer to the administration method used in original Russian clinical trials but carries higher risks associated with self-administration and product purity. This method should only be considered under the direct supervision of a healthcare provider experienced in peptide therapy. - Original clinical dose: 10 mg intramuscular injection on 5 consecutive days, every 6 months - Injectable peptides carry sterility risks — require pharmaceutical-grade product, sterile technique, and physician oversight - Not recommended for self-administration

What to monitor: Evaluating the impact of pineal-derived peptides involves tracking subjective markers of sleep quality and recovery, as well as objective data from wearable devices. Because specific blood biomarkers for these peptides are not yet validated, individual monitoring focuses on the functional improvements reported in early clinical observations. - Sleep quality: Pinealon's primary anecdotal benefit is deeper, more restorative sleep — track via a sleep wearable - Morning alertness: Users commonly report cleaner waking with no grogginess - HRV (Heart Rate Variability): A useful proxy for recovery quality - There are no validated biomarkers that specifically measure Epitalon or Pinealon efficacy in humans

Safety considerations: The safety profile of synthetic Epitalon and Pinealon is largely inferred from long-term studies of the crude pineal extract, which showed no severe adverse events over several years of intermittent use. However, users should remain aware of the theoretical implications of telomerase activation and the lack of comprehensive data regarding modern synthetic formulations. - No severe adverse events reported in the published 3-year epithalamin clinical trials - Oral ultrashort peptides are small enough to survive gut transit, but systemic bioavailability data in humans is limited - Theoretical concern: telomerase activation could theoretically be counterproductive in individuals with undiagnosed early-stage cancer — inform your physician - No drug interaction data exists; use caution if on any prescription medications - Not studied in pregnancy, breastfeeding, or individuals under 40

Scientific citations

Expert perspectives

Related interventions